Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sputum

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    624 result(s) found for: Sputum. Displaying page 2 of 32.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-007244-33 Sponsor Protocol Number: LPA112046 Start Date*: 2009-04-08
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: The efficacy of orally administered GSK2190915 as an add-on to current therapy in subjects with moderate to severe asthma who have elevated sputum neutrophils
    Medical condition: Moderate to severe asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001026-62 Sponsor Protocol Number: ETGOL Start Date*: 2021-10-05
    Sponsor Name:University Hospital Dr Josep Trueta
    Full Title: Benefits of inhalation of 7% hypertonic saline solution prior to ELTGOL physiotherapy, in patients with bronchiectasis. A randomized controlled trial.
    Medical condition: bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10038738 - Respiratory, thoracic and mediastinal disorders 10006445 Bronchiectasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014412-35 Sponsor Protocol Number: ARD-3100-0901 Start Date*: 2010-02-23
    Sponsor Name:Aradigm Corporation
    Full Title: An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Administration of Two Strengths of Ciprofloxacin f...
    Medical condition: Non-cystic fibrosis bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10006446 Bronchiectasis NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004110-32 Sponsor Protocol Number: D1521C00002 Start Date*: 2005-12-01
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase II Study to Assess The Efficacy of AZD9056 (single oral 400 mg dose) when Administered for 4 Weeks in Patients wit...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001749-42 Sponsor Protocol Number: 484/12 Start Date*: 2012-08-07
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Effects of treatment and withdrawal with inhaled beclomethasone/formoterol on lung inflammation in COPD.
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10029977 Obstructive chronic bronchitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021472-28 Sponsor Protocol Number: D3550C00014 Start Date*: 2011-01-10
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the efficacy of 28-Day Oral Administration of AZD5069 Twice Daily in Patients with Bronchiectasis.
    Medical condition: Bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006445 Bronchiectasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-004699-34 Sponsor Protocol Number: D4260C00008 Start Date*: 2008-10-28
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase II study to Assess the efficacy of 28 Day Oral Administration of AZD1236 in Adult Patients with Cystic Fibrosis.
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011763 Cystic fibrosis lung LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-002335-33 Sponsor Protocol Number: KKS287 Start Date*: 2022-05-18
    Sponsor Name:Philipps University Marburg
    Full Title: Inhaled ColiFin® in adult bronchiectasis patients with new asymptomatic Pseudomonas aeruginosa infection– an open-label, proof of concept - randomized controlled trial
    Medical condition: bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10038738 - Respiratory, thoracic and mediastinal disorders 10006445 Bronchiectasis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003723-29 Sponsor Protocol Number: JBT101-CF-002 Start Date*: 2018-05-11
    Sponsor Name:Corbus Pharmaceuticals, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
    Medical condition: Cystic Fibrosis (CF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) HU (Completed) SE (Completed) FR (Completed) PT (Completed) SK (Completed) AT (Completed) BE (Completed) ES (Completed) BG (Completed) NL (Completed) CZ (Completed) GR (Completed) PL (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2005-004899-21 Sponsor Protocol Number: TR02-104 Start Date*: 2005-12-22
    Sponsor Name:Transave, Inc.
    Full Title: Safety and tolerability study of SLIT(TM) Amikacin 500 mg once daily for 14 days by inhalation in cystic fibrosis study subjects chronically infected with Pseudomonas aeruginosa.
    Medical condition: Cystic Fibrosis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000924-14 Sponsor Protocol Number: S52549 Start Date*: 2011-05-23
    Sponsor Name:KU Leuven LRD
    Full Title: Development and validation of a sputum biomarker mRNA panel for the diagnostic work-up of asthma
    Medical condition: asthma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003688-25 Sponsor Protocol Number: INS1007-301 Start Date*: 2021-04-08
    Sponsor Name:Insmed Incorporated
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibros...
    Medical condition: Non-Cystic Fibrosis Bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    23.0 10038738 - Respiratory, thoracic and mediastinal disorders 10083611 Non-cystic fibrosis bronchiectasis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Completed) DK (Completed) NL (Completed) IE (Completed) HU (Completed) GR (Completed) PL (Completed) BG (Completed) LT (Prematurely Ended) SK (Completed) AT (Completed) FR (Completed) EE (Prematurely Ended) BE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-000166-35 Sponsor Protocol Number: 54939 Start Date*: 2016-08-08
    Sponsor Name:Noordwest Ziekenhuisgroep
    Full Title: Effects of long term ToBrAmycin InhalaTion SoluTion (TIS) once daiLy on Exacerbation rate in patients with non-cystic fibrosis bronchiectasis. A double blind, randomized, placebo and TIS twice dai...
    Medical condition: Patients with non-cystic fibrosis bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10070295 Infective exacerbation of bronchiectasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-005142-12 Sponsor Protocol Number: TMC207-C203 Start Date*: 2005-06-25
    Sponsor Name:Tibotec Pharmaceuticals Limited
    Full Title: An open-label study to evaluate the extended early bactericidal activity, safety, tolerability and pharmacokinetics of multiple doses (m.d.) of TMC207 oral solution (os) and isoniazid (JH), m.d. of...
    Medical condition: Tuberculosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004986-99 Sponsor Protocol Number: NBTCS02 Start Date*: 2017-01-11
    Sponsor Name:NovaBiotics, Ltd
    Full Title: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Investigating the Optimal Dose Regimen, Efficacy, and Safety of Adding Oral Cysteamine in Adult Patients with Cystic Fibrosis (C...
    Medical condition: exacerbation of Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10070608 Infective pulmonary exacerbation of cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001728-30 Sponsor Protocol Number: MPEX-204 Start Date*: 2008-08-26
    Sponsor Name:Mpex Pharmaceuticals, Inc.
    Full Title: A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Efficacy of Three Dosage Regimens of MP- 376 Solution for Inhalation Given for 2...
    Medical condition: Pseudomonas aeruginosa infection in patients suffering from stable Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011763 Cystic fibrosis lung LLT
    9.1 10021860 Infection pseudomonas aeruginosa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-002949-11 Sponsor Protocol Number: 601-0014 Start Date*: 2019-08-05
    Sponsor Name:Pulmatrix, Inc.
    Full Title: A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Itraconazole Administered as a Dry Powder for Inhalation (PU...
    Medical condition: Asthma with Allergic Bronchopulmonary Aspergillosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10006474 Bronchopulmonary aspergillosis allergic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017257-35 Sponsor Protocol Number: R015 Start Date*: 2010-02-25
    Sponsor Name:Revotar Biopharmaceuticals AG
    Full Title: Multi-center, randomized, double-blind, placebo-controlled, cross-over Phase II study to evaluate the safety and efficacy of inhaled Bimosiamose for the treatment of patients with moderate to sever...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002340-40 Sponsor Protocol Number: A9111004 Start Date*: 2014-10-16
    Sponsor Name:Pfizer Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled 2-Way Crossover Study to Evaluate the Efficacy, Safety and Tolerability of PF-03715455 Administered Twice Daily By Inhalation for 4 Weeks in Subjects ...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005229-31 Sponsor Protocol Number: 242-07-204 Start Date*: 2008-02-14
    Sponsor Name:Otsuka Pharmaceutical Development and Commercialization, Inc.
    Full Title: A Multi center, Randomized, Double-blind, Placebo-controlled Phase 2 Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Multiple Doses of OPC-67683 in Patients with Pulmonary Sputum Cu...
    Medical condition: Pulmonary Multidrug-resistant Tuberculosis (MDR TB)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037440 Pulmonary tuberculosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Completed) LV (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 17:04:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA